(MedPage Today) — SAN FRANCISCO — Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials, the reporting of those results has been inconsistent for prostate, kidney, and bladder cancer trials…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
